I |
I. Control |
None |
4 |
II-1 |
II. Electrical stimulation |
None |
5 |
II-2 |
|
Injection of naloxone in the ARC (central antagonism) |
4 |
II-3 |
|
Injection of saline in the ARC (central blank) |
4 |
II-4 |
|
Peripheral subconjunctival injection of 0.2 ml naloxone (peripheral antagonism) |
4 |
II-5 |
|
Peripheral subconjunctival injection of 0.2 ml saline (peripheral blank) |
4 |
III-1 |
III. DAMGO injection |
Injection of DAMGO in the ARC (2 µmol/µl) |
4 |
III-2 |
|
Injection of DAMGO in the ARC (4 µmol/µl) |
4 |
III-3 |
|
Subconjunctival injection of 0.2 ml naloxone+injection of DAMGO in the ARC (2 µmol/µl) |
4 |
|
|
(peripheral antagonism) |
|
III-4 |
|
Subconjunctival injection of 0.2 ml saline+injection of DAMGO in the ARC (2 µmol/µl) (peripheral blank) |
3 |
IV-1 |
IV. DPDPE injection |
Injection of DPDPE in the ARC (2 µmol/µl) |
4 |
IV-2 |
|
Injection of DPDPE in the ARC (4 µmol/µl) |
4 |
IV-3 |
|
Subconjunctival injection of 0.2 ml naloxone+injection of DPDPE in the ARC (2 µmol/µl) |
3 |
|
|
(peripheral antagonism) |
|
IV-4 |
|
Subconjunctival injection of 0.2 ml saline+injection of DPDPE in the ARC (2 µmol/µl) (peripheral blank) |
3 |